Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | DHODH | Q02127 | 3/20 | 0.66 |
| ▸ | TACR3 | P29371 | 8/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6209856 | 0.83 | KDM4E (0.76) | KDM4ELMNASMN1; SMN2PDE10ATSHR | |
| Cinchophen SCHEMBL25519 | 0.82 | KDM4E (1.00) | KDM4ELMNASMN1; SMN2PDE10ADHODH | |
| Cinchophen SCHEMBL7588217 | 0.82 | KDM4E (1.00) | KDM4ELMNASMN1; SMN2PDE10ADHODH | |
| Cinchophen SCHEMBL29376617 | 0.82 | KDM4E (1.00) | KDM4ELMNASMN1; SMN2PDE10ADHODH | |
| SCHEMBL28957908 | 0.81 | MEN1 (0.62) | KDM4ELMNASMN1; SMN2CYP3A4MEN1 | |
| SCHEMBL28672244 | 0.81 | KDM4E (0.64) | KDM4ELMNASMN1; SMN2PDE10ATSHR | |
| SCHEMBL29859762 | 0.81 | TSHR (1.00) | KDM4ELMNASMN1; SMN2PDE10ATSHR | |
| Cinchophen SCHEMBL10757475 | 0.81 | KDM4E (0.97) | KDM4ELMNASMN1; SMN2PDE10ADHODH | |
| Cinchophen SCHEMBL4464779 | 0.81 | KDM4E (0.97) | KDM4ELMNASMN1; SMN2PDE10ADHODH | |
| Cinchophen SCHEMBL4805149 | 0.81 | KDM4E (0.97) | KDM4ELMNASMN1; SMN2PDE10ADHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | SHY Therapeutics LLC | 2023-09-14 | — | — | US | disclosed |
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | SHY Therapeutics LLC (US) | 2023-05-18 | — | — | US | disclosed |
| US-11026930-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2021-06-08 | — | — | US | disclosed |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
| US-20100129800-A1 | POLYMERS AND THEIR USE AS FLUORESCENT LABELS | AYMAMI BOFARULL JUAN | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | MAPK6, MAP3K6, MAPK4 | KDM4E 3392/4885LMNA 3509/4885SMN1; SMN2 4331/4885 |
| US-20100129800-A1 | POLYMERS AND THEIR USE AS FLUORESCENT LABELS | CBR3, H1-0, H1-3 | KDM4E 3889/4885LMNA 80/4885SMN1; SMN2 3821/4885 |
| US-11026930-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | KDM4E 4215/4885LMNA 3109/4885SMN1; SMN2 3555/4885 |
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | HRAS, KRAS, NRAS | KDM4E 4215/4885LMNA 3109/4885SMN1; SMN2 3555/4885 |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | KDM4E 3392/4885LMNA 3509/4885SMN1; SMN2 4331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.